InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,180.74
(
1.03%
)
US TECH 100
17,601.60
(
1.05%
)
Dow Jones
38,852.27
(
0.46%
)
Brent Oil
83.38
(
0.31%
)
Bitcoin
63,476.16
(
-0.82%
)
Post# of 270
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

bassfishing101

Send PM Follow Ignore
Followers 8
Posts 2112
Boards Moderated 0
Alias Born 04/06/2008

bassfishing101

Re: None

Tuesday, 01/06/2009 6:20:59 AM

Tuesday, January 06, 2009 6:20:59 AM

Post# of 270
GNTA should rocked today with the news Genta Incorporated announced that the Company has received notice from the U.S. Food and Drug Administration (FDA) that tesetaxel, the latest addition to Genta's oncology product portfolio, has been granted designation as an "Orphan Drug" for treatment of patients with advanced gastric cancer. Orphan drug status provides for a period of marketing exclusivity, certain tax benefits, and an exemption from certain fees upon submission of a New Drug Application. As a late Phase 2 agent, the Company believes tesetaxel is the leading oral taxane currently in clinical development.


Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up